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Liver fibrosis is a phenomenon of excessive accumulation of 
extracellular matrix (ECM) proteins in response to liver 
damage. Hepatic stellate cells (HSCs) are known to be a group 
of cells that are activated during liver fibrosis and differentiate 
into myofibroblasts and play a key role in liver fibrosis. 
Activated HSCs express alpha smooth muscle actin (αSMA), a 
myofibroblast marker, secrete ECM proteins such as collagen. 
Our team identified a new mechanism of liver fibrosis in 
previous studies. In normal liver, an anti-fibrotic factor called 
transcriptional intermediary factor 1 gamma (TIF1γ)
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suppresses αSMA expression to inactivate in HSCs. However, 
during liver fibrosis, TGF(transforming growth factor)β1 
decreases TIF1γ expression and increases αSMA expression, 
which activate HSCs. Activated HSCs overexpresses ECM 
proteins such as collagen and eventually causes liver fibrosis.
My hypothesis is that restoring the lowered TIF1γ
expression of activated HSCs would inhibit HSCs activation and 
result in liver fibrosis mitigation. The TGFβ promoter-TIF1γ
vector (pTGFβ-TIF1γ) was constructed to restore TIF1γ
expression in activated HSCs. In vitro experiments were 
conducted using LX2, human HSCs cell line. As a result, αSMA, 
activated HSCs marker was reduced when the pTGFβ-TIF1γ
vector was transfected. Next, I tried to confirm the effect of 
pTGFβ-TIF1γ on liver fibrosis in vivo. Before that, I used 
VitA-coupled liposome as a tool to deliver vectors specifically 
to HSCs and confirmed that VitA-coupled liposome transferred 
vectors specifically to HSCs. And I confirmed the fibrosis 
mitigation effect of pTGFβ-TIF1γ in liver fibrosis model with 
thioacetamide (TAA). 
These results showed the importance of TIF1γ in the HSCs as 
anti-fibrotic factor and the mitigation effect of pTGFβ-TIF1γ
iii
on liver fibrosis. I think this study verified the possibility of 
liver fibrosis gene therapy.
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LIST OF ABBREVIATIONS
HSCs : Hepatic stellate cells.
aHSCs : Activated hepatic stellate cells (Fibrotic state).
qHSCs : Quiescent hepatic stellate cells (Normal state).
TIF1γ: Transcriptional intermediary factor 1 gamma.
CDS : Coding sequence.
αSMA : Alpha smooth muscle actin.
TAA : Thioacetamide.
VitA-coupled liposome: Vitamin A conjugated liposome.
IP injection : Intraperitoneal injection.
IV injection : Intravenous injection.
pTGFβ-TIF1γ : TGFβ promotor + CDS of TIF1γ.
ALR : Augmenter of liver regeneration.
EPLIN : Epithelial protein lost in neoplasm.
MBNL1 : Muscleblind-like protein 1.
Nm23-H1 : Nonmetastatic protein 23, homolog 1.
PIAS1 : Protein inhibitor of activated stat1.
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ALT : Alanine aminotransferase.
AST : Aspartate aminotransferase.  
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INTRODUCTION
Liver fibrosis is excessive accumulation of extracellular matrix 
protein (ECM) caused by repeated liver damage. 1, 2 Excess 
accumulated ECM proteins during liver fibrosis destroy the 
hepatic architecture by forming fibrous scars and inhibit
function of liver by suppressing regeneration of hepatocytes. 1, 2
Liver fibrosis further develops into liver failure, which only 
effective therapy is transplantation. 1, 2 However, many 
researchers are looking for different therapeutic strategies
because of the lack of available liver for transplantation and the 
side effects of immunosuppressant after transplantation. 3
Recent advanced technologies have identified the cellular 
mechanisms of liver fibrosis. Among them, HSCs activation is 
the key mechanism of ECM production during liver fibrosis 
process. 
HSCs were activated by TGFβ, which is increased during liver 
fibrosis, and is transformed into myofibroblast. Activated HSCs
(aHSCs) accelerates liver fibrosis by increasing its proliferation 
and ECM production 4
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In our previous study, we confirmed that hE-MSCs (Embrionic 
mesenchymal stem cells) secreted a large amount of HGF 
(Hepatocyte growth factor), which plays an important role in 
liver. 5, 6 We performed in vivo experiments to determine 
whether hE-MSCs is effective on liver fibrosis. Mouse liver 
slide was stained with MT (Masson’s trichrome) staining. As a 
result, the liver surface undulation and fibrosis area were 
significantly decreased in the hE-MSCs injected group. 
HSC activation is an event of fibrosis caused by TGFβ, 
increased pro-fibrotic factors during liver fibrosis. We found 
anti-fibrotic factors to evaluate the mitigation effect of hE-
MSC on liver fibrosis in vitro. First, six anti-fibrotic factors
candidate (ALR, EPLIN, MBNL1, Nm23-H1, PLAS1, TIF1γ) 
were screened by putting the ‘negative regulator of 
TGFβ’in pubmed. Using real-time PCR, three candidates 
(EPLIN, NM23-H1, TIF1γ) that showed decreased expression 
level in activation of LX2 cells were selected. Among those
factors, TIF1γ was the only factor that decreased when 
activated by TGFβ and increased again by hE-MSCs. Next, 
knock down of TIF1γ by si-RNA results in the increased level 
of αSMA, HSCs activation marker. Furthermore, increased 
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αSMA was reduced when TIF1r was overexpressed by 
lentivirus. Based on these results, we derived TIF1γ as anti-
fibrotic factor that prevent activation in HSCs.
We have identified the HSCs activation mechanism and found 
TIF1γ as anti-fibrotic factor through subsequent studies. 
Briefly, TIF1γ could block HSCs activation by suppressing 
expression of αSMA in quiescent HSCs (qHSCs) under normal 
condition. However, when liver injury occurs, expression of 
TIF1r was reduced by TGFβ in HSCs. And then, expression of 
αSMA was increased by reducing TIF1γ.  As a result, HSCs
was activated and liver fibrosis is accelerated.
Based on this mechanism, My hypothesis is that TIF1γ
restoration in aHSCs would return to qHSCs and relieve liver 
fibrosis. In vitro experiments using human hepatic stellate cell 
line (LX2) and in vivo experiments using mouse liver fibrosis 




All animal study protocols were approved by the Institutional 
Animal Care and Use Committee (IACUC) of Seoul National 
University Hospital, Korea. Male 12–13-week-old BALB/c-
nude mice weighing 20–25 g were used for experiments. To 
induce liver fibrosis, TAA was injected into mice at a 200 
mg/kg concentration (Sigma-Aldrich, St. Louis, MO, USA) by 
intraperitoneal injection. Vector (pTGFβ-GFP, pCMV-GFP, 





10mM Retinol (R7632, Sigma) 280nmol + 1mM Lipotrust 
[Cationic liposome] (CSR-LEO-10-EX, Cosmobio) 140nmol 
per mouse. Then leave for 5 minutes at RT.
-VitA-liposome, Vector conjugation
Vortex vitA-liposome 140nmol with 18ug vector (pTGFβ-
GFP, pTGFβ-TIF1γ, pCMV-TIF1γ) per mouse. Then leave 
for 20 minutes at RT. 
-VitA-liposome-vector complex filtering
Add the solution to Vivaspin2 (concentrator, PES column, 
VS0221, VIVASIENCE) and 1500g centrifugation for 5min at 
25℃ 3times.
Reverse the column, then add 100ul of PBS and 3000g 
centrifugation for 2min at 25℃.
LX2 culture
The human hepatic stellate cell line LX2 was a generous gift 
from Dr. Friedman 7. LX2 cells were grown in high-glucose 
DMEM supplemented with GlutaMax (Gibco, Grand Island, NY, 
USA), 2% FBS, and 1% (v/v) penicillin/streptomycin (Gibco) 
(LX2 complete medium) at 37°C in a humidified incubator with 
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5% CO2. 
In order to examine the fibrosis mitigation effect of pTGFβ1-
TIF1γ vector in activated HSCs, 10 ng/ml of rhTGFβ1(7754-
bh-005, R&D) was pre-treated for 3days and then pTGFβ1-
TIF1γ vector was transfected with Fugene HD. (Promega) and 
rhTGFβ1 was treated for 3days.
Antibodies
Rabbit polyclonal a-TIF1γ (ab84455, Abcam), rabbit
polyclonal a-TIF1γ (ab47062, Abcam), mouse monoclonal a-
αSMA (A5228; Sigma), rabbit polyclonal a-αSMA (ab5694, 
Abcam), rabbit polyclonal a-Collagen 1(PA5-29569, Thermo 
Fisher), rabbit polyclonal a-GAPDH (ab9485, Abcam) and 
mouse monoclonal a-GAPDH (ma5-15738, Thermo) were 
used for immunoblot assays.
Immunohistochemistry 
Mouse livers were perfused with cold PBS and removed. The 
livers were fixed in a 4% para-formaldehyde solution (Wako), 
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embedded in paraffin, and cut into serial sections (4–5-µm 
thick). Paraffin sections were stained with Masson Trichrome 
stain (MT stain), Picro-Sirius red using standard protocols. 
Picro-Sirius red staining was used to detect collagen to 
visualize connective tissues. Images were obtained using a 
Leica light microscope (Leica, Wetzlar, Germany). To evaluate 
the therapeutic effect of pTGFβ-TIF1γ on liver fibrosis, the 
percentage of fibrotic liver area was estimated by quantitative 
image analysis of Picro-Sirius red-stained sections using the 
ImageJ (National Institutes of Health, Bethesda, MD, USA) 
software. 
qRT-PCR analysis
Total RNA was isolated from cultured cells using the Trizol
(Thermo Fisher, 15596026) according to the manufacturer’s 
instructions. cDNA was synthesized from 1ug RNA using 
Reverse Transcription Master Premix (ELPIS Biotech, EBT-
1512, Daejeon, Korea). qPCR was carried out using the 
FastStart Universal SYBR Green Master (Rox) (Roche, 04 913 
914 001, Basel, Swizerland) in an ABI PRISM-7500 sequence 
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detection system (Applied Biosystems). Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) and protein phosphatase 1 
α (PP1A) were used as an internal control to calculate relative 
changes in gene expression. Primers were designed using the 
Primer blast site (National Center for Biotechnology 
Information) and synthesized by Macrogen (Seoul, Korea). 
The following primers were used: 
GAPDH, forward: 5′-AAGGTCGGAGTCAACGGATTT -3′, 
reverse: 5′- GTTCTCAGCCTTGACGGTGC -3′;
PP1A: forward 5′- CATAATGGCACTGGTGGCAAG-3′, 
reverse: 5′- GCCATCCAACCACTCAGTCTT-3′;
αSMA, forward: 5′-GGCAAGTGATCACCATCGGA-3′, 
reverse: 5′-TCTCCTTCTGCATTCGGTCG-3′;
TIF1γ, forward 5′- CTCCGGGATCATCAGGTTTA -3′, 
reverse: 5′- TCAACATGCAAGCACTCCTC -3′; 
Col1A: forward 5′- CTGCCGTGACCTCAAGATGT-3′, 
reverse: 5′- CCGAACCAGACATGCCTCTT-3′;
Western Blot
Total protein was isolated from cells with RIPA cell lysis buffer 
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(Thermo Fischer), supplemented with complete protease 
inhibitor cocktail (Genedepot) and Phoshotase inhibitor cocktail 
(Genedepot). Lysates were incubated on ice for 15min and 
13000rpm Centrifugation for 10min at 4℃, Protein 
concentration was determined by BCA assay (Cat. 23223, 
Thermo Fisher). Proteins were separated on 10%SDS-PAGE 
gels and transferred from gel onto polyvinyl difluoride (PVDF) 
membrane. The membrane was blocked with 5% normal horse 
serum in PBS and incubated overnight at 4℃ with primary 
antibodies. Detection was done using ECL HRP 
Chemiluminescent substrate. Western blot figures were 
quantified by Image J(NIH). 
Serum assay
Blood samples were drawn from the hearts of anesthetized mice.
Serum was separated by centrifugation at 3,000 rpm for 15 min 
and stored at −80°C until analysis. To test liver function after 
TAA treatment, ALT and AST activities were measured using 
an automatic chemistry analyzer (Hitachi 7070) according to 
the manufacturer’s instructions. AST and ALT activities were 
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determined following the manufacturer’s procedure and were 
expressed as mU/ml.
Statistical analysis
Statistical analysis was performed using the GraphPad Prism 6 
software (GraphPad Software, La Jolla, CA, USA). Data are 
expressed as the mean ± SEM. Differences between groups 
were analyzed by the unpaired t-test and one-way analysis of 




pTGFβ-TIF1γ vector construct strategy as a gene 
therapy for liver fibrosis 
During liver fibrosis, increased TGFβ acts on TGFβ promotor 
to increase expression of TGFβ and increase αSMA
expression by reducing TIF1γ expression. Increased TGFβ
accelerates HSCs activation and liver fibrosis by forming the 
autocrine loop of TGFβ signaling 8. 
pTGFβ-TIF1γ vector was constructed to rescue TIF1γ
upon activation of TGFβ promoter in HSCs. I thought that 
TGFβ increased TIF1γ when pTGFβ-TIF1γ vector was 
transfected in LX2 cell. And then increased TIF1γ restores
aHSCs to qHSCs, which consequently relieves liver fibrosis.
12
(Figure1, A)
The reason using the TGF promoter rather than commonly 
used CMV promoter is that the expression of the vector can 
be controlled depending on the state of the liver fibrosis 
[Normal (TGFβ↓) vs Fibrosis (TGFβ↑)].
pTGFβ-TIF1γ vector can restore quiescent state of 
hepatic stellate cell.
In order to confirm whether pTGFβ-TIF1γ vector can 
restore quiescent state of HSCs, in vitro experiments were 
performed using human HSCs cell line LX2. TGFβ was 
treated daily after transfection to confirm that the pTGFβ-
TIF1γ vector works well. (Figure2, A)As a result, mRNA 
expression level of αSMA (aHSCs marker) and collagen1
were significantly reduced in TGFβ treated groups. 
(Figure2, B)And protein expression level of αSMA was also 
reduced in TGFβ treated groups. (Figure2, C, D) So I could 
confirm that pTGFβ-TIF1γ vector works well. 
As the original concept is the therapy, TGFβ was pre-
treated for 3days to activate HSCs and then vector 
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(pTGFβ-TIF1γ, pCMV-TIF1γ) was transfected. TGFβ
was further treated for 2 days to make the vector work and 
then harvested. (Figure2, E)As a result, it was confirmed 
that mRNA and protein level of αSMA and collagen1 that 
was increased by TGFβ were significantly decreased in 
vector transfected group. (Figure2, F, G, H)
Based on these results, I verified that pTGFβ-TIF1γ
vector can restore the aHSCs to quiescence condition.
The vitamin A-coupled  liposome is a tool that transfer 
vectors specifically to hepatic stellate cell in vivo.
Next, I adopted the VitA-coupled liposome as a delivery tool 
to specifically transfer the pTGFβ-TIF1γ vector to HSCs
before conducting in vivo experiments. I briefly explain the 
mechanism of VitA-coupled liposome that specifically 
transfers vectors to HSCs in vivo. The vectors are wrapped 
around the liposome and VitA (Retinol) is attached to the 
liposome. When VitA-coupled liposomes enter the 
bloodstream, retinol binding proteins (RBP) in the blood 
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attach to VitA. HSCs is the cell that stores most retinol in the 
body so RBP-VitA-coupled liposomes go to HSCs in liver. 
Next, the RBP attached to the liposome bind to the RBP 
receptor in  HSCs. Consequently, the vectors enter the 
HSCs by receptor. 9 (Figure3, A)
The pCMV-GFP vector was injected with VitA-coupled 
liposome through intravenous (IV) and intraperitoneal (IP) 
injection. Both injection pathways showed that the vector 
was well transferred to cells that looks like HSCs in liver.
(Figure3, B, C) Retinol (HSCs marker in liver) was also seen 
to determine whether the GFP expressing cells are HSCs. 
Consequently, GFP expressing cells were co-localized with 
retinol, so I confirmed that VitA-coupled liposome can 
deliver vector to HSCs. (Figure3, D)
Moreover, I also checked through the confocal image that 
vector did not go to other organs. (Figure3, E) These results 
demonstrate that VitA-coupled liposome is a delivery tool 
that specifically transfer the vector to HSCs in vivo.
pTGFβ-TIF1γ vector can alleviate liver fibrosis in vivo
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Previously, pTGFβ-TIF1γ vector was confirmed in vitro to 
restore aHSCs, and VitA-coupled liposome was confirmed in 
vivo to deliver the vector to HSCs specifically. Based on 
these results, I conducted  in vivo expreiments using 
mouse liver fibrosis model (TAA model) to confirm whether 
the pTGFβ-TIF1γ vector actually alleviated liver fibrosis. In 
pilot study, TAA was injected three times to induce liver 
fibrosis. And then the vector was injected with VitA-coupled 
liposome. After that, TAA was injected three times to 
accelerate the fibrosis and sampling was performed to 
confirm the degree of fibrosis. (Figure4, A) Liver slides 
were stained through Picro-sirus red staining (red) and MT
staining (blue) to see collagen deposit. As a result, liver 
surface undulation and fibrosis area were significantly 
reduced in pTGFβ-TIF1γ vector injected group. (Figure4, 
B) Therefore, I verified the possibility of mitigating liver 
fibrosis of the pTGFβ-TIF1γ vector.
Then the additional experiment was performed to increase 
the number of experiments. TAA was injected three times to 
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induce liver fibrosis. And then the vector was injected with
VitA-coupled liposome. (Figure4, C) I confirmed that 
fibrosis was well induced at the time of vector injection 
(10D). (Figure4, D) After that, TAA was injected five times 
to accelerate the fibrosis and sampling was performed to 
confirm the degree of fibrosis. As a result, the liver fibrosis 
area was significantly reduced in pTGFβ-TIF1γ vector 
injected group compare to pTGFβ-GFP injected group. 
(Figure4, E, F) In addition, protein level of αSMA was 
significantly reduced in pTGFβ-TIF1γ vector treated 
group. (Figure4, G, H) Also ALT and AST, which are 
indicators of liver damage in mouse serum, were significantly 
reduced compared to TAA group. (Figure4, I)
Based on these results, I verified that liver fibrosis was 
alleviated when pTGFβ-TIF1γ was transferred to HSCs
using VitA-coupled liposome.
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Figure1. pTGFβ-TIF1γ vector construct strategy as a gene 
therapy for liver fibrosis.
(A)The diagram for the strategy. TGFβ transfers the signal 
through the receptor into the cell, and the transferred signal 
activates TGFβ promoter to form an autocrine loop and 
decrease the TIF1γ.  After Reduced TIF1γ increases αSMA 
and ECM proteins. Consequently, HSCs is activated and fibrosis 
is accelerated. When pTGFβ-TIF1γ vector is transfected to 
activated HSCs, TIF1r is restored by TGFβ. Restoring TIF1γ
can reduce αSMA and ECM proteins. As a result, HSCs is 
restored quiescent state and then fibrosis is alleviated. 
(A) Graphical abstract
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(A) Time table (LX2)
(B) Real-time PCR (LX2)
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(C) Western blot (LX2)
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(D) Quantification-Western blot (LX2)
(E) Time table (LX2)
(F) Real time-PCR (LX2)
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(G) Western blot (LX2)
(H) Quantification-Western blot (LX2)
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Figure2. pTGFβ-TIF1γ vector can restore quiescent state 
of hepatic stellate cell.
(A)TGFβ (10 ng/ml) was treated on LX2 for 7 and 10times to 
activate pTGFβ-TIF1γ vector after transfection.
(B) mRNA expression levels of αSMA and collagen 1 were 
significantly reduced in TGFβ treated group at 7 and 10days.
(C) Protein expression level of αSMA was significantly 
reduced in TGFβ treated group at 7 and 10days.
(D)Quantification of western blot band (αSMA) using imageJ 
program. 
(E) TGFβ(10 ng/ml) was treated on LX2 for 3times to induce 
aHSCs and then pTGFβ-TIF1γ was transfected. After 
transfection, TGFβ was treated for 3days to activate the 
vector.
(F) mRNA expression levels of αSMA and collagen 1 were 
significantly reduced in vector transfected groups. (pTGFβ-
TIF1γ, pCMV-TIF1γ) 
(G) Protein expression levels of αSMA and collagen 1 were 
significantly reduced in vector transfected groups. (pTGFβ-
TIF1γ, pCMV-TIF1γ) 




(B) Confocal image (mouse liver)
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(C) Confocal image (mouse liver)
(D) Confocal image (mouse liver)
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(E) Confocal image (Other organs)
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Figure3. Vitamin A-coupled  liposome is a tool that 
transfer vectors specifically to hepatic stellate cell.
(A) Diagram of VitA-coupled liposome vector delivery 
mechanism into HSCs in vivo.
(B) Mouse liver confocal microscopy image when pCMV-GFP 
vector was wrapped in a VitA-coupled liposome and injected 
through the IP and IV routes. Nucleus was stained with DAPI 
(blue) and pCMV-GFP vector transfected cells expressed 
green fluorescence. Both injection routes well delivered the 
vector to liver in vivo.
(C) Cell that pCMV-GFP vector was delivered (green) in liver 
looks like HSCs.
(D)GFP expressing cell was co-localized with retinol that 
HSCs marker in liver. Retino auto-fluorescence (excitation-
335 nm, emission-458 nm)




(A) Time table (mouse) - pilot
(B) Picro-Sirius red, MT staining (mouse liver)
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(C) Time table (mouse)
(D) Picro-Sirius red staining (mouse liver)
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(E) Picro-Sirius red staining (mouse liver)
(F) Quantification of fibrosis area
34
(G) Western blot (mouse liver)
(H) Quantification-Western blot (mouse liver)
(I) ALT, AST levels (mouse serum)-IU/L
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Figure4. TGFβ-TIF1γvector can alleviate liver fibrosis in 
vivo.
(A)Timetable showed schedule of animal experiment. TAA 
(200 mg/kg) was injected 3times through IP injection to induce 
fibrosis. And then,  vector(pCMV-GFP, pTGFβ-TIF1γ) was 
injected 1time through IP injection. Next TAA was injected 
3times to Aggravate fibrosis and harvested liver after 2days.
(B)Picro-sirius red and MT staining showed reduction of 
collagen accumulation by treatment of pTGFβ-TIF1γ on 
mouse liver fibrosis model. 
(C) Timetable showed schedule of animal experiment. TAA 
(200 mg/kg) was injected 3times through IP injection to induce 
fibrosis. And then, vector(pTGFβ-GFP, pTGFβ-TIF1γ) was 
injected 1time through IP injection. Next TAA was injected 
5times to more Aggravate fibrosis and harvested liver after 
2days.
(D) Picro-sirius red staining that stain collagen in red was 
performed. Fibrosis was induced at vector injection point(10D). 
Fibrosis area (red) of pTGFβ-TIF1γ vector injected group 
was reduced compare to TAA group. 
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(E) Picro-sirius red staining that stain collagen in red was 
performed. Fibrosis area and liver surface undulation were 
reduced in pTGFβ-TIF1γ group compare to TAA group and 
pTGFβ-GFP group.
(F) Fibrosis area was quantified by measuring the ratio of 
fibrosis area (red area / total area). The fibrosis area of pTGF
β-TIF1γ group was significantly reduced compared to the 
pTGFβ-GFP group.
(G) Protein expression levels of αSMA was significantly 
reduced in pTGFβ-TIF1γvector group.
(H) Quantification of western blot band (αSMA) using imageJ 
program.
(I) ALT and AST serum levels were measured using automatic 
chemistry analyzer (Hitachi 7070). ALT and AST serum levels 
were significantly reduced in pTGFβ-TIF1γ group compare 
to TAA group.
* Group of in vivo study (pilot)
- Non treat (N=2)
- TAA+pCMV-GFP (N=3), 
- TAA+pTGFβ-TIF1γ(N=1)
*Group of in vivo study
-Non treat (N=3)






HSCs activation plays a key role in pathological progression of 
liver fibrosis. HSCs activation is triggered by increased in 
TGFβ level during liver fibrosis. The pathophysiologic role of 
TGFβ in the liver is well-known. TGFβ initiates inflammation 
and fibrosis, and ultimately plays an important role in the 
progression to cirrhosis and cancer.10 In liver fibrosis, TGFβ
induces activation and transformation of HSCs to turn into 
myofibroblast expressing αSMA. TGFβ phosphorylates 
SMAD 2/3 and interacts with SMAD4.11  The SMAD2 / 3-
SMAD4 complex is attached to the (SMAD binding 
element)SBE site of DNA to activate αSMA expression.12, 13
Therefore, targeting HSCs activation mechanisms that interfere 
with the signaling pathway may be useful in liver fibrosis 
therapy. 
TIF1γ is known to be a factor that inhibits the TGFβ signaling 
pathway by binding to phosphorylated SMAD2 / 3 through 
competition with SMAD4 14-16 In previous studies, we
confirmed that TIF1γ interacts with SMAD2 / 3 and bind to the 
αSMA promotor in human HSCs cell line (LX2). And TIF1γ-
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SMAD2 / 3 complex inhibits αSMA expression by binding to 
the αSMA promoter. Thus, TIF1γ inhibited αSMA 
expression in HSCs, indicating that it is an anti-fibrotic factor 
that prevents HSCs activation. (In previous study)
Based on the results of previous studies, I established a 
therapeutic strategy for liver fibrosis using TIF1γ. I want to 
restore TIF1γ in activated HSCs during the fibrosis process. I 
focused TGFβ, which increases during liver fibrosis 
progression and plays a key role in HSCs activation. Once 
TGFβ signal is turned on, TGFβ secretion is amplified 
through positive autocrine feedback. 8, 17 Based on the TGFβ
signaling mechanism, a vector was constructed by conjugating 
TIF1γ CDS to the TGFβ promoter, in which TGFβ promoter 
is activated and TIF1γ is restored when exogenous TGFβ
acts on HSCs. 
The anti-fibrotic effect of the pTGFβ-TIF1γ vector was 
verified by the reduction of αSMA and collagen 1 when the 
vector was transfected into LX2. To validate the anti-fibrotic 
effect of the vector in vivo, we needed a delivery tool to 
specifically delivery vector to HSCs. Vitamin A (retinol)
complexes with retinol binding protein (RBP) in the body and is 
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delivered to the HSCs, retinol reservoir. Based on this 
mechanism, we used the Vitamin A-coupled liposome as a tool 
to specifically delivery vector to HSCs. 18, 19 pTGFβ-TIF1γ
vector was tested in vivo using a vitamin A-coupled liposome, 
and liver fibrosis was alleviated in the vector treated group.
In conclusion : In previous studies, we identified TIF1r, which 
plays a key role in the HSCs activation mechanism. And I
established a liver fibrosis therapy strategy at the cellular level 
that restores TIF1r in activated HSCs during liver fibrosis.
40
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국문초록
TIF1γ restoring vector 를 이용한 간 섬유화





간 섬유화는 간 손상에 대한 반응으로 extracellular matrix 
(ECM) 단백질이 초과로 쌓이는 현상입니다. 간 성상 세포는 간
섬유화 과정 중 활성화 되어 myofibroblast 로 분화되고, 간을
경화 시키는데 핵심 역할을 하는 세포 군으로 잘 알려져 있습니다.
활성화된 간 성상 세포는 myofibroblast marker 인 alpha smooth 
muscle actin (αSMA) 을 발현하며 collagen 과 같은 ECM 
단백질을 분비하여 간을 경화 시키는데 기여합니다.
저희 팀은 이전 연구에서 새로운 간 섬유화 기전을 밝혔습니다.
간이 정상인 상태에서는 간 성상 세포 내 transcriptional 
intermediary factor 1 gamma (TIF1γ) 라는 항 섬유화 인자가
αSMA 발현을 막아 비활성 상태를 유지하고 있습니다. 하지만 간
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섬유화 과정에서는 TGFβ1 에 의해 TIF1γ 발현양이 감소하게
되고 그로 인해 억제되고 있던 αSMA 발현양이 증가하게 됨으로써
간 성상 세포가 활성화 됩니다. 활성화 된 간 성상 세포는 collagen 
과 같은 ECM 단백질을 초과 생성하게 되고, 결국에 간 섬유화가
진행됩니다.
저는 이전 연구에서 밝힌 간 섬유화 기전을 바탕으로 활성화 된
간 성상 세포 내에 낮아진 TIF1γ 발현을 다시 회복시켜준다면 간
성상 세포의 활성화가 억제되고, 그 결과로 간 섬유화가 완화될
것이라고 생각하였습니다. 간 성상세포에서 TIF1γ 발현을
회복시키기 위하여 TGFβ promotor-TIF1γvector (pTGFβ-
TIF1γ)를 제작하였습니다. 그리고 in vitro 에서 pTGFβ-
TIF1γ가 TGFβ에 의해 증가한 αSMA (활성화된 간 성상세포
표지자) 를 감소 시키는 것을 사람의 간 성상 세포주인 LX2 에서
확인하였습니다. 이 후 pTGFβ-TIF1γ의 간 섬유화 완화 효과를
in vivo 에서 확인하고자 하였습니다. 그 전에 vector 를 간 성상
세포에 특이적으로 전달하는 도구로 Vit A-coupled liposome 을
채택하였고, 간 성상 세포에 특이적으로 vector 를 전달하는 것을
in vivo 실험에서 확인하였습니다. 그 후 TAA(Thioacetamide) 간
섬유화 동물 모델에서 pTGFβ-TIF1γ의 섬유화 완화 효과를
확인하였습니다.
이러한 결과를 통해 저는 간 섬유화 과정 중 간 성상 세포 내 항
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섬유화 유전자 TIF1γ의 중요성 및 pTGFβ-TIF1γ의 간 섬유화
완화 효과를 확인 할 수 있었습니다. 저는 이 연구가 간 섬유화
유전자 치료의 가능성을 확인 시켜주었다고 생각합니다.
………………………………………………………………………………
주요어 : VitA-coupled liposome, 유전자 치료, pTGFβ-
TIF1γ vector, 간 성상 세포; HSCs, 간 섬유화, 
TIF1γ(transcriptional intermediary factor 1 gamma), 
αSMA (alpha smooth muscle actin), aHSCs (활성화 된
상태의 간 성상 세포), qHSCs (비활성화 상태의 간 성상 세포)
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